Ultragenyx Pharmaceutical (NASDAQ: RARE – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report released Saturday to clients and investors.
RARE has been the subject of several other research reports. Cowen lowered his target price on shares of Ultragenyx Pharmaceutical from $86.00 to $65.00 in a Thursday, Nov. 3, report. Citigroup cut its price target on shares of Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, August 3, report. Cowen reduced his target price on Ultragenyx Pharmaceutical from $86.00 to $65.00 in a Thursday, Nov. 3 research note. Barclays lowered its price target on Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday July 29 research note. Finally, Wedbush reiterated a “neutral” rating on Ultragenyx Pharmaceutical shares in a Thursday, October 13 research note. One equity research analyst has assigned the stock a sell rating, two have issued a hold rating and eight have assigned the company’s stock a buy rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.86.
Ultragenyx Pharmaceutical Price Performance
NASDAQ:RARE shares opened at $36.55 on Friday. The company’s fifty-day moving average price is $41.01 and its 200-day moving average price is $49.98. Ultragenyx Pharmaceutical has a 12-month low of $33.62 and a 12-month high of $88.22. The company has a market capitalization of $2.56 billion, a P/E ratio of -3.75 and a beta of 1.20.
Separately, CFO Mardi Dier sold 3,484 shares of the company in a trade on Wednesday, October 12. The shares were sold at an average price of $38.22, for a total value of $133,158.48. Following the sale, the CFO now owns 68,324 shares of the company, valued at approximately $2,611,343.28. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. 6.70% of the shares are held by company insiders.
Institutional entries and exits
Several institutional investors and hedge funds have recently increased or reduced their stake in the stock. Connor Clark & Lunn Investment Management Ltd. increased its position in Ultragenyx Pharmaceutical by 478.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 188,421 shares of the biopharmaceutical company worth $7,803,000 after purchasing an additional 155,840 shares last quarter. ExodusPoint Capital Management LP acquired a new position in Ultragenyx Pharmaceutical during Q3 worth approximately $1,159,000. Seven Eight Capital LP acquired a new position in Ultragenyx Pharmaceutical during Q3 worth approximately $532,000. Tower Research Capital LLC TRC increased its position in Ultragenyx Pharmaceutical by 32.1% during Q3. Tower Research Capital LLC TRC now owns 7,005 shares of the biopharmaceutical company worth $290,000 after buying 1,703 additional shares last quarter. Finally, Bank of Montreal Can acquired a new position in Ultragenyx Pharmaceutical during Q3 worth approximately $4,788,000. Institutional investors and hedge funds hold 88.27% of the company’s shares.
Ultragenyx Pharmaceutical Company Profile
(Get a rating)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to firstname.lastname@example.org.
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here